

506 E1  
D2

27. (amended) A method of delivering a therapeutic agent to CD30<sup>+</sup> malignant cells, comprising contacting said cells with a conjugate comprising one or more therapeutic agents attached to a soluble CD30 ligand (CD30-L) polypeptide, wherein said soluble CD30-L polypeptide is capable of binding a CD30 polypeptide consisting of amino acids 19-390 of SEQ ID NO:1, and further wherein the amino acid sequence of said CD30-L is at least 90% identical to amino acids 49-220 of SEQ ID NO:19 or amino acids 47-215 of SEQ ID NO:23.

28. (amended) A method of delivering a therapeutic agent to CD30<sup>+</sup> malignant cells, comprising contacting said cells with a conjugate comprising one or more therapeutic agents attached to a soluble CD30-L polypeptide, wherein said soluble CD30-L polypeptide is capable of binding a CD30 polypeptide consisting of amino acids 19-390 of SEQ ID NO:1 and further wherein said soluble CD30-L is encoded by a DNA that is capable of hybridizing under conditions of moderate stringency to the nucleotide sequence of SEQ ID NO:22, wherein said hybridization conditions comprise hybridizing at 55° in 5 X SSC.

3-28 29 (amended) A method according to claim 28, wherein said conjugate is administered in an effective amount to a human afflicted with said malignant cells.

32 31 (amended) A method according to claim 29, wherein said soluble CD30-L polypeptide is in the form of an oligomer comprising two or more soluble CD30-L polypeptides, wherein the soluble CD30-L polypeptides are each selected from the group consisting of:

- 33
- a) amino acids 49-220 of SEQ ID NO:19; and
  - b) amino acids z-215 of SEQ ID NO:23, wherein z is amino acid 44, 45, 46 or 47 of SEQ ID NO:23.

Please cancel claim 34. ✓

Please cancel claim 35. ✓

Please cancel claim 36. ✓

Please cancel claim 37. ✓

Please cancel claim 41. ✓

Please cancel claim 44. ✓

34 64 261 (amended) A method according to claim 61, wherein the toxin is selected from the group consisting of ricin, abrin, diphtheria toxin, *Pseudomonas aeruginosa* exotoxin A, ribosomal inactivating proteins and a mycotoxin.

Please cancel claim 67.

50624 68. (amended) A method according to claim 50, wherein the soluble CD30-L polypeptide is fused with a human IgG1 Fc region.

3 169. (amended) A method according to claim 50, wherein the soluble CD30-L polypeptide is in the form of an oligomer comprising two or more soluble CD30-L polypeptides, wherein the soluble CD30-L polypeptides are each selected from the group consisting of:

- a) amino acids 49-220 of SEQ ID NO:19; and
- b) amino acids z-215 of SEQ ID NO:23, wherein z is amino acid 44, 45, 46 or 47 of SEQ ID NO:23.

Please add the following new claim:

32 170. (New) A method according to claim 62, wherein the toxin is saporin toxin.

#### REMARKS

Claims 27-30, 32-45 and 50-69 are currently under consideration in the application and stand rejected under one or more of 35 U.S.C. § 112, first and second paragraphs, § 102 and § 103. Claims 27, 28, 29, 32, 36, 62, 68 and 69 have been amended as indicated above, and claims 34, 35, 36, 37, 41, 44 and 67 have been cancelled from the application. New claim 70 has been added to the application.

Claims 34 and 67 were cancelled because the subject matter they covered is essentially covered in other claims now pending. Claims 35-37, 41 and 44 have been cancelled because they depended directly or indirectly from cancelled claim 34.

The amendments to claims 27 and 28 include the addition of the modifier "malignant" before "cell" and the modifier "soluble" before "CD30-L polypeptide." Support for "malignant" is found in originally filed claim 29 and throughout the specification, for example, at page 3, lines 29-32 and at page 14, lines 16-20. Support for amending "CD30-L" to "soluble CD30-L" is found, for example, in cancelled claim 34 and throughout the specification, for example, at page 7, line 10 to page 8, line 8, and in Example 11, at pages 42, line 4 to page 43, line 2. The sequences for soluble CD30-L recited in amended claim 27 are supported throughout the specification, for example, at page 7, line 31 to page 8, line 8 and at page 42, lines 7-9. Claim 27 is amended further by the addition of language referring to percent amino acid sequence identity, which is supported throughout the specification,